Literature DB >> 9802890

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.

S L Rowland-Jones1, T Dong, K R Fowke, J Kimani, P Krausa, H Newell, T Blanchard, K Ariyoshi, J Oyugi, E Ngugi, J Bwayo, K S MacDonald, A J McMichael, F A Plummer.   

Abstract

Many people who remain persistently seronegative despite frequent HIV exposure have HIV-specific immune responses. The study of these may provide information about mechanisms of natural protective immunity to HIV-1. We describe the specificity of cytotoxic T lymphocyte responses to HIV in seronegative prostitutes in Nairobi who are apparently resistant to HIV infection. These women have had frequent exposure to a range of African HIV-1 variants, primarily clades A, C, and D, for up to 12 yr without becoming infected. Nearly half of them have CTL directed towards epitopes previously defined for B clade virus, which are largely conserved in the A and D clade sequences. Stronger responses are frequently elicited using the A or D clade version of an epitope to stimulate CTL, suggesting that they were originally primed by exposure to these virus strains. CTL responses have been defined to novel epitopes presented by HLA class I molecules associated with resistance to infection in the cohort, HLA-A*6802 and HLA-B18. Estimates using a modified interferon-gamma Elispot assay indicate a circulating frequency of CTL to individual epitopes of between 1:3,200 and 1:50,000. Thus, HIV-specific immune responses-particularly cross-clade CTL activity- may be responsible for protection against persistent HIV infection in these African women.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802890      PMCID: PMC509124          DOI: 10.1172/JCI4314

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.

Authors:  H Cao; P Kanki; J L Sankalé; A Dieng-Sarr; G P Mazzara; S A Kalams; B Korber; S Mboup; B D Walker
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians.

Authors:  M R Betts; J Krowka; C Santamaria; K Balsamo; F Gao; G Mulundu; C Luo; N N'Gandu; H Sheppard; B H Hahn; S Allen; J A Frelinger
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development.

Authors:  S C Threlkeld; P A Wentworth; S A Kalams; B M Wilkes; D J Ruhl; E Keogh; J Sidney; S Southwood; B D Walker; A Sette
Journal:  J Immunol       Date:  1997-08-15       Impact factor: 5.422

Review 4.  HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy.

Authors:  G L Ada; M J McElrath
Journal:  AIDS Res Hum Retroviruses       Date:  1997-02-10       Impact factor: 2.205

5.  Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission.

Authors:  P Putkonen; B Mäkitalo; D Böttiger; G Biberfeld; R Thorstensson
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Global distribution of the CCR5 gene 32-basepair deletion.

Authors:  J J Martinson; N H Chapman; D C Rees; Y T Liu; J B Clegg
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

7.  Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis.

Authors:  R Bertoni; J Sidney; P Fowler; R W Chesnut; F V Chisari; A Sette
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

8.  The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression.

Authors:  N L Michael; G Chang; L G Louie; J R Mascola; D Dondero; D L Birx; H W Sheppard
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

9.  HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.

Authors:  S Mazzoli; D Trabattoni; S Lo Caputo; S Piconi; C Blé; F Meacci; S Ruzzante; A Salvi; F Semplici; R Longhi; M L Fusi; N Tofani; M Biasin; M L Villa; F Mazzotta; M Clerici
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

10.  Rapid effector function in CD8+ memory T cells.

Authors:  A Lalvani; R Brookes; S Hambleton; W J Britton; A V Hill; A J McMichael
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

View more
  107 in total

Review 1.  The search for an HIV vaccine.

Authors:  Malegapuru William Makgoba; Nandipha Solomon; Timothy Johan Paul Tucker
Journal:  BMJ       Date:  2002-01-26

Review 2.  Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses.

Authors:  R Kaul; S L Rowland-Jones; J Kimani; T Dong; H B Yang; P Kiama; T Rostron; E Njagi; J J Bwayo; K S MacDonald; A J McMichael; F A Plummer
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

4.  HIV versus the immune system: another apparent victory for the virus.

Authors:  N L Letvin; B D Walker
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 5.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

6.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

7.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity.

Authors:  Alessandro Sette; John Sidney; Huynh-Hoa Bui; Marie-France del Guercio; Jeff Alexander; John Loffredo; David I Watkins; Bianca R Mothé
Journal:  Immunogenetics       Date:  2005-03-04       Impact factor: 2.846

Review 9.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.